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Only 2.4% of the 16.5Kb mitochondrial genome (mtDNA) shows homoplasmic variation at >1% 
frequency in humans. Migration patterns have contributed to geographic differences in the 
frequency of common genetic variants, but population genetic evidence implicates selection 5 
shaping the evolving mtDNA phylogeny. It is not clear how and when this occurs. 
Unlike the nuclear genome, mtDNA is maternally transmitted and there are many copies 
in each cell. Initially a new genetic variant only affects a proportion of the mtDNA 
(heteroplasmy). A reduction in the amount of mtDNA per cell during female germ cell 
development causes a genetic bottleneck. This leads to the rapid segregation of mtDNA 10 
molecules and different heteroplasmy levels between siblings. Although primarily governed by 
random genetic drift, there is evidence of selection occurring during this process in animals. 
However, it has been difficult to demonstrate this convincingly in humans.  
 
RATIONALE 15 
To determine whether there is selection for or against heteroplasmic mtDNA variants during 
transmission we studied 12,975 whole genome sequences, including 1,526 mother-offspring 
pairs where 45.1% had heteroplasmy affecting >1% of mtDNA molecules. Harnessing both the 
mtDNA and nuclear genome sequences, we then determined whether the nuclear genetic 
background influenced mtDNA heteroplasmy, validating our findings in another 40,325 20 
individuals.   
 
RESULTS 
Novel mtDNA variants were less likely to be inherited than known variants, where the level of 
heteroplasmy tended to increase on transmission. Variants in the ribosomal RNA genes were less 25 
likely to be transmitted, and variants in the non-coding displacement (D)-loop were more likely 
to be transmitted. MtDNA variants predicted to affect the protein sequence tended to have lower 
heteroplasmy levels than synonymous variants. In 12,975 individuals, there was a correlation 
between the location of heteroplasmic sites and known D-loop polymorphisms, including the 
absence of variants in critical sites required for mtDNA transcription and replication.  30 
 4 
We defined 206 unrelated individuals where the nuclear and mitochondrial genomes were 
from different human populations. In these, new population-specific heteroplasmies were more 
likely to match the nuclear genetic ancestry than the mitochondrial genome on which the 
mutations occurred. These findings were independently replicated in 654 informative 
individuals.  5 
 
CONCLUSION 
The characteristics of mtDNA in the human population are shaped by selective forces acting on 
heteroplasmy within the female germ line, and are influenced by the nuclear genetic background. 
The signature of selection can be seen over one generation, ensuring consistency between these 10 






Germline selection of human mitochondrial DNA is shaped by the nuclear genome. Top 
left: Initially new mtDNA variants are heteroplasmic, with the proportion changing during 5 
maternal transmission. Bottom left: Selection during the transmission of mtDNA heteroplasmy. 
Transmitted variants are more likely have been seen before as homoplasmic polymorphisms. 
Right: New haplogroup-specific variants are more likely to match the nuclear genetic ancestry 
than the mtDNA ancestry.  
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Abstract: ~2.4% of the human mitochondrial genome (mtDNA) shows common homoplasmic 
genetic variation. Analyzing 12,975 whole genome sequences we show that 45.1% of individuals 
from 1,526 mother-offspring pairs harbor a mixed population of mtDNA (heteroplasmy), but the 
propensity for maternal transmission differs across the mitochondrial genome. Over one 
generation, we observe selection both for and against variants in specific genomic regions, and 5 
previously seen variants were more likely to be transmitted. New heteroplasmies were more 
likely to match the nuclear genetic ancestry than the mitochondrial genome on which the 
mutations occurred, validating our findings in 40,325 individuals. Thus, human mtDNA at the 
population level is shaped by selective forces within the female germline under nuclear genetic 
control to ensure consistency between the two independent genetic lineages. 10 
One Sentence Summary: Human mitochondrial DNA (mtDNA) undergoes selection in the 
female germ line which is shaped by the nuclear genome.    
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Primarily inherited from the maternal line, the 16.5Kb human mitochondrial DNA (mtDNA) 
genome acquired mutations sequentially following the emergence of modern humans out of 
Africa (1-3). Pedigree and phylogenetic analyses have estimated a de novo mtDNA nucleotide 
substitution rate of ~10-8/base pair/year (4). However, from 30,506 mitochondrial genome 
sequences from across the globe (5), only 2.4% of nucleotides show genetic variation with 5 
frequencies greater than 1% within a population (Fig. 1). Although contentious (6, 7), selection 
could explain the non-random distribution of common variants across the mitochondrial genome 
in the human population.  
Heteroplasmic mtDNA variants are common and maternally inherited 
We analyzed high-depth mtDNA sequences from 1,526 mother-offspring pairs (mean depth in 10 
the mothers = 1,880x, range 249x-7,454x; mean depth in the offspring = 1,901x, range 259x-
7,475x; mothers vs. offspring, P=0.49, two-sample t-test) (fig. S1). We called homoplasmic and 
heteroplasmic mtDNA variants from whole-blood DNA sequence data (8, 9) and filtered out 
heteroplasmic calls likely to be due to errors (9, 10, 11). We identified a mixed population of 
mtDNA (heteroplasmic variants) with a heteroplasmic variant allele frequency (VAF) >1% with 15 
high confidence in 47.8% of mothers (1,043 heteroplasmic variants at 812 sites) and 42.5% of 
offspring (893 heteroplasmic variants at 693 sites) (Fig. 1, table S1 and Data S1). In 22 
individuals, where the whole genome was independently sequenced twice, the heteroplasmic 
mtDNA calls were 96.4% concordant (fig. S2) (9). As expected (12, 13), there was a small but 
significant positive correlation between the number of heteroplasmic variants and age of mother 20 
(P=6.42 x 10-11, R2=0.17, CI= 0.12 - 0.23, Pearson's correlation) (fig. S3), with mothers having 
more heteroplasmic variants than offspring (mean number in the mothers = 0.68, range 0-6; 
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mean number in the offspring = 0.58, range 0-4; P=0.002, effect size = 0.68, Wilcoxon rank sum 
test) (Fig. 2A).  
We defined three categories of heteroplasmic variants: (1) transmitted/inherited, if the 
variant was present in the mother and the offspring and was heteroplasmic in at least one of the 
two; (2) lost, if the heteroplasmic variant was present in the mother but not detectable in the 5 
offspring; and (3) de novo, if the heteroplasmic variant was present in the offspring but not 
detectable in the mother (table S1) (9).  Note that very low level heteroplasmies (<1% VAF) 
may be missed by our sequencing and bioinformatics pipeline. Hence, “lost” and “de novo” 
variants could potentially be present at very low levels in, respectively, the offspring’s and 
mother’s germline. The heteroplasmic fraction (HF) of transmitted heteroplasmic variants (mean 10 
HF = 19.5%, sd = 13.9%) was significantly higher than the HF of lost variants (mean HF = 5.6%, 
sd = 6.3%) in the mothers (P<2.2 x 10-16, effect size = 4.24, Wilcoxon rank sum test); and the HF 
of inherited heteroplasmic variants (mean HF = 19.8%, sd = 14.1%) was significantly higher 
than the HF of de novo variants (mean HF = 6.2%, sd = 7.4%) in the offspring (P<2.2 x 10-16, 
effect size = 4.06, Wilcoxon rank sum test) (Fig. 2B and table S1). The HF of transmitted 15 
variants in the offspring strongly correlated with the corresponding maternal level (P=1.52 x 10-
93, R2=0.79, CI=0.75 - 0.82, Pearson's correlation) (Fig. 2C). In total, 477 de novo heteroplasmic 
variants were observed at >1% HF in the offspring that were not seen in the mother, in keeping 
with previous estimates (13). To ensure these data were not due to technical errors, we 
determined whether any heteroplasmic variants in the offspring were also present in their fathers. 20 
Amongst 313 father-offspring pairs, the offspring harbored 196 heteroplasmic variants with HF 
>1%, and only one of these was also observed in the corresponding father. This was a common 
population variant (population minor allele frequency (MAF) = 25.8% (5)) in the D-loop region 
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(m.152T>C) which was homoplasmic in the father and had an HF of 12.4% in his child. The 
alternate allele was not detected in the mother, suggesting this is a recurrent site of mutation or 
conceivably due to the paternal transmission of mtDNA. 
The difference between HF in mothers and their offspring can be measured in percentage 
points (Fig. 2D)(14). This metric is limited by the difference between the HF of the mother and 5 
the boundaries 0 and 100% and the magnitude of the percentage change does not correspond 
with the magnitude of the fold-change in VAF. For example, a change from 50% to 55% would 
be given the same value as a change from 1% to 6%, even though the latter implies 6-fold 
increase in the proportion of mtDNA carrying the alternate allele. We therefore studied the log2 
ratio of HF between offspring and mothers after imputation of HF values below 1% to our 10 
detection threshold of 1% (subsequently termed the heteroplasmy shift (HS), Fig. 2, E and F) 
(9), which shrunk HSs towards zero only when the true HF in either the mother or the offspring 
was below 1%. 
Overall, there was no significant difference between the number of heteroplasmic variants 
with a positive (n=731) and a negative (n=798) HS (P=0.091, binomial test). The HS distribution 15 
around zero was moderately symmetric and gave a marginal P value for asymmetry (P=0.05, one 
sample t-test) (Fig. 2, D and E), consistent with random segregation of mitochondria during 
meiosis (14, 15). All of the HSs were <6 in magnitude, corresponding to a <64-fold increase or 
decrease in HF across one generation, with 3 exceptions. De novo variants at m.57T>C 
(HF=99.3%), m.8993T>G (HF=82.1%) and m.14459G>A (HF=93.6%) were detected in three 20 
unrelated offspring and not present in the corresponding mothers (figs. S4 to S6). m.14459G>A 
is a non-synonymous (NS) variant in ND6 which, on the basis of evidence from previously 
published pedigrees (16, 17), causes Leber hereditary optic neuropathy (LHON) and Leigh 
 10 
syndrome/dystonia. m.8993T>G is a NS variant in ATP6 (L156R), which has been observed on 
many independent occasions in Leigh syndrome or neurogenic ataxia with retinitis pigmentosa 
(18-20). Although these extreme HSs could reflect differences in the mechanism of transmission 
for pathogenic mtDNA mutations (21), ascertainment is a more likely explanation because 
childhood-onset neurodegenerative diseases were recruited as part of this study (22). 5 
Ascertainment bias is unlikely to explain the de novo occurrence of m.57T>C, but these findings 
indicate that extreme HSs at moderate HFs are not typical of human populations. 
As expected, the non-coding displacement (D)-loop had the highest substitution frequency 
(7.64 x 10-5 /base/genome/transmission) of all the regions in the mitochondrial genome (Fig. 3A 
and table S2)(13). In total, we observed 16 out of 57 previously defined (5) pathogenic 10 
mutations in the 1,526 mother-offspring pairs (Fig. 3B). After excluding m.14459G>A and 
m.8993T>G, where the extreme HS likely reflects ascertainment bias, the mean HS for the 
remaining 14 pathogenic mutations was not significantly different from zero (P=0.22, one 
sample t-test), nor from the mean HS for the remaining 1,076 non-pathogenic variants (P=0.11, 
two sample t-test). Thus, overall we did not see a strong signature of selection for or against 15 
pathogenic alleles, although our statistical analysis does not preclude that a subset of the 
observed pathogenic alleles may be under selection. Intriguingly, only three mothers carried the 
most common heteroplasmic pathogenic mutation m.3243A>G (23), each with a low HF (5.2%, 
3.6% and 1.7%), which decreased in the corresponding offspring, to levels falling below our 
detection threshold in two of the three offspring (3.9%, <1% and <1%). Six of the 16 pathogenic 20 
mutations were not detectable in the mothers, giving a de novo mutation rate for known 
pathogenic mutations of 393/100,000 live births (95% CI 144 – 854), which is ~3.7-fold higher 
than previously reported (24).  
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To gain insight into possible mutational mechanisms, we determined the trinucleotide 
mutational signature. As shown previously, C>T and T>C substitutions were the most common 
type of substitution in homoplasmic variants (5) and cancer somatic mtDNA mutations (25). For 
heteroplasmic variants, C>T and T>C substitutions were also predominant, although we also 
observed a small but significant excess of C>A, C>G, T>A and T>G substitutions (P<2.2 x 10-5 
16, odd ratio = 0.36, CI = 0.29 - 0.44, Fisher’s exact test) (fig. S7). Given that the heteroplasmic 
variant signature was not identical to the homoplasmic variant signature, this suggests that the 
germline transmission shapes the mutational signatures seen in homoplasmic variants at the 
population level.  Also of note, de novo mutations were more likely to involve a CpG-containing 
trinucleotide (P=3.01 x 10-6, odd ratio = 0.50, CI = 0.38 - 0.66, Fisher’s exact test) (Fig. 3C). 10 
Although controversial (26), this could be because methylation of NpCpG sites on the mtDNA 
genome predisposes to de novo mtDNA mutations, as seen in the nuclear genome.  
Known mtDNA variants are more likely to be transmitted than novel 
We then compared heteroplasmic variants which have been seen before in the general population 
(known) and those not previously observed (novel). Variants were considered novel if they were 15 
absent from the 1000 Genomes datasets and dbSNP and were seen in at most one individual 
amongst 30,506 NCBI mtDNA sequences (5). Novel heteroplasmic variants were 4.7-fold less 
commonly transmitted from mother to offspring than known variants (P=3.55 x 10-13, odd 
ratio=2.60, CI=1.97 - 3.45, Fisher’s exact test), and the HS for transmitted known variants was 
more likely to be positive (P=0.0002, probability=0.40, CI=0.35 - 0.45, binomial test) (Fig. 3, D 20 
and E). Also, the transmitted heteroplasmic variants were more likely to affect known 
haplogroup-specific sites (27) compared to the lost and de novo heteroplasmic variants (P=7.86 x 
10-11, odds ratio=0.40, CI=0.30-0.53, and P=0.0016, odds ratio=0.62, CI=0.46-0.84, respectively, 
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Fisher’s exact test) (Fig. 3F). This suggests that factors may modulate the transmission of 
mtDNA heteroplasmy within the female germline over a single generation and influence the 
likelihood that they become established within human mtDNA populations. As heteroplasmic 
variants are acquired throughout life, they must be removed at transmission to offspring at a 
higher rate than they appear de novo as, otherwise, each generation would be accompanied by an 5 
expected increase in the number of heteroplasmic variants which may be deleterious (28). In 
keeping with this, the number of novel variants present in the mother but not transmitted (lost 
variants), exceeded the number of de novo novel variants detected in the offspring (P=7.93 x 10-
7, probability=0.62, CI= 0.57 - 0.67, binomial test) (Fig. 3D), in part reflecting the accumulation 
of heteroplasmic variants with increasing age in the mothers (fig. S3).  10 
Selection for and against heteroplasmy in different genomic regions 
We analyzed different functional regions of the genome and found evidence indicating region-
specific selection for or against heteroplasmic variants. The distributions of HF in the 1,526 
mother-offspring pairs were significantly different between the D-loop, rRNA, tRNA, and 
coding regions (Fig. 4A and table S3). Within the coding region, the NS and synonymous (SS) 15 
variants also had different distributions (P=2.74 x 10-5, Kolmogorov-Smirnoff test). The NS/SS 
ratio was greater for the heteroplasmic variants than for the homoplasmic variants (P=3.98 x 10-
24, odds ratio=1.91, CI=1.68 - 2.18, Fisher’s exact test), and the de novo and lost heteroplasmic 
variants had a higher NS/SS than the transmitted variants (transmitted vs de novo: P=0.0056, 
odds ratio=1.69, CI=1.15 - 2.48; transmitted vs lost: P=0.01, odds ratio=1.57, CI=1.10 - 2.24, 20 
Fisher’s exact test) (Fig. 4B). The heteroplasmic variants were more often in conserved sites than 
the homoplasmic variants (P=3.71 x 10-77, odds ratio=3.21, CI=2.86 - 3.60, Fisher’s exact test), 
and the transmitted heteroplasmic variants were less conserved than the de novo (P=0.0018, odds 
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ratio=1.62, CI=1.19 - 2.22, Fisher’s exact test) and lost (P=9.60 x 10-9, odds ratio=2.25, CI=1.69 
- 3.03, Fisher’s exact test) heteroplasmic variants (Fig. 4C). Also, heteroplasmic variants with a 
positive HS were less conserved than those with a negative HS (P=0.03, odds ratio=1.28, 
CI=1.01 - 1.61, Fisher’s exact test). Variants in the rRNA genes were more likely to show a 
decrease in the heteroplasmy level on transmission than an increase (P=1.00 x 10-4, 5 
probability=0.65, CI=0.57 - 0.72, binomial test) (Fig. 4D), and the mean HS was significantly 
less than zero (P=8.21 x 10-5, d=0.30, one sample t-test) (Fig. 4E).  
In order to understand the determinants of transmission of heteroplasmic variants with a 
reduced risk of confounding, we used multi-variable logistic regression to model the probability 
of transmission across all 1,526 mother-offspring pairs (9). We modeled the transmission 10 
probability of a variant as a function of its HF in the mother, the identity of the mitochondrial 
genome region containing it, and its known vs novel status (Fig. 4, F to H and Fig. 3D) (9). The 
probability that a heteroplasmic variant in the mother was transmitted to her offspring was 
associated with its HF in the mother (P<2.2 x 10-16, coefficient estimate=1.17, sd=0.08, logistic 
regression) (Fig. 4F). Variants in the D-loop were more likely to be transmitted (P=0.04, 15 
coefficient estimate=0.39, sd=0.19, logistic regression) than average and those in the rRNA were 
less likely to be transmitted (P=0.0026, coefficient estimate=-0.94, sd=0.31, logistic regression) 
than average (Fig. 4G). The novel variants were less likely to be transmitted than the known 
variants (P=0.028, coefficient estimate=0.43, sd=0.19, logistic regression) (Fig. 3D), even after 
accounting for all other covariates, including HF in the mothers.  20 
Heteroplasmic variants in the non-coding Displacement (D-) loop 
To cast light on the possible effects of selection on the non-coding D-loop, we derived a high-
resolution map of heteroplasmic variants in 12,975 individuals, which included the 1,526 
 14 
mother-offspring pairs (mean mtDNA genome depth = 1832x, sd=945x; mean depth of D-loop = 
1569x, sd=819x) (Fig. 5, A to C and fig. S8) (9). We found an association between the 
homoplasmic allele frequency amongst 30,506 NCBI mtDNA sequences and the proportion of 
individuals heteroplasmic for the same allele (P<2.2 x 10-16, logistic regression) (Fig. 5, A to C) 
similar to that previously observed (5). Of the 17 regions in the D-loop (Fig. 5C bottom - purple 5 
and orange bars), two had a significantly greater number of heteroplasmic variants than expected 
by chance. These regions correspond to the proposed replication fork barrier associated with the 
D-loop termination sequence (MT-TAS2) (29) and MT-CSB1 (MT-TAS2: P=4.5 x 10-11, odds 
ratio=0.40, CI=0.30 - 0.54; MT-CSB1: P=7.0 x 10-6, odds ratio=0.39, CI=0.24 - 0.61, Fisher’s 
exact test vs remainder of the D-loop). 10 
To help understand the evolution of the D-loop, we identified all the heteroplasmic variants 
not identified on mtDNA phylogenies across a subset of 10,210 unrelated individuals from the 
original dataset (9). Five of these heteroplasmic variants were shared by more than one 
individual and were present exclusively in people with a particular haplogroup (Fig. 5, D and E). 
One variant (m.16237A>T) was present in multiple individuals from two different branches of 15 
the phylogeny (L0a1&2 and M35b2) (Fig. 5, D and E). Compared to homoplasmic sequences 
from across the world (5), only m.299C>A was observed previously as a homoplasmic variant 
(in 3/30,506 individuals), each time on the R30b1 haplogroup background. This suggests that 
individuals we saw who were heteroplasmic for m.299C>A (Fig. 5F), also descended from the 
same maternal ancestor as the three homoplasmic individuals seen previously (5), but belonged 20 
to a closely related maternal lineage that had not yet reached fixation. These recurrent 
heteroplasmies contributed to the distinct trinucleotide mutational signature of the D-loop (P=2.3 
x 10-137, Stouffer’s method for combining Fisher P values), which involves prominent non-
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canonical substitutions, and is consistent with the conclusion that the homoplasmic trinucleotide 
mutational signature of mtDNA is shaped by germline transmission of heteroplasmic variants 
(Fig. 5D and fig. S9).  
We observed an absence of low-level heteroplasmic variants in critical sites required for the 
initiation of mtDNA transcription and replication. These zones include several conserved 5 
sequence boxes and the light strand promoter (MT-LSP: P=7.7 x 10-18, odds ratio=10.12, 
CI=5.43 – 20.31, Fisher’s exact test), which are required for mtDNA transcription and mtDNA 
replication (30). Certain regions with no known function (31) (eg. 16,400-16,500; Fig. 5C) also 
had a complete lack of low-level heteroplasmic variants, which suggests that an intact sequence 
at these regions is essential for mitochondrial function, perhaps genome propagation. The 10 
coordinates of the conserved and non-conserved regions provide a guide for functional studies of 
the mtDNA D-loop which has been incompletely characterized to date. 
The nuclear genetic background influences the heteroplasmy landscape 
Most of the ~1,500 known mitochondrial proteins are synthesized from the nuclear genome, 
including the majority of polypeptide subunits of the oxidative phosphorylation system, and the 15 
machinery required to replicate and transcribe the mitochondrial genome in situ (1). Selection for 
or against specific mtDNA variants must therefore occur in the context of a specific nuclear 
genetic background. To explore this, we identified 12,933 individuals for whom a confident 
mtDNA haplogroup could be predicted (fig. S10). We compared the haplogroup of each 
individual with the corresponding nuclear genetic ancestry, and identified three distinct groups of 20 
individuals: (1) a haplogroup matched group (n=11,867, 91.7%) where the mtDNA haplogroup 
was concordant with the nuclear ancestry; (2) a mismatched group (n=295, 2.3%) where the 
nuclear ancestry and mtDNA were from different human populations; and, (3) a group where the 
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nuclear ancestry could not be reliably determined (n=771, 6.0%) (Fig. 6, A and B and fig. S10). 
Subsequent analyses focused on the haplogroup matched and mismatched groups (9).  
8,159 heteroplasmic variants at 3,854 of the 16,569 distinct sites on the mitochondrial 
genome were present in the matched group, and 195 heteroplasmic variants at 163 distinct sites 
were present in the mismatched group. The mean number of heteroplasmic variants and mean 5 
HF were not statistically different between the matched and mismatched groups (fig. S11). Next, 
we studied distinct heteroplasmic sites in the 10,179 of 12,933 individuals who were not related 
on the basis of their nuclear genome (9,414 in the matched group, 217 in the mismatched group 
and 548 in the other group). Distinct heteroplasmic sites were more likely to affect known 
haplogroup specific sites (27) than the rest of the mitochondrial genome (P<2.2 x 10-16, Fisher’s 10 
exact test), particularly within the mismatched group (P=0.001, odds ratio=1.70, CI=1.22 - 2.36, 
Fisher’s exact test) (Fig. 6C). 
We extracted 2,641 haplogroup-specific variants present in only one super-population 
(European, Asian or African) on the world mtDNA phylogeny (27). We built a predictive model 
of transmission of these variants using logistic regression in 9,385 unrelated European and Asian 15 
nuclear ancestries using 2,215 European (n=940) and Asian (n=1,275) specific variants on the 
mtDNA phylogeny, omitting the Africans because of the diversity and small number (figs. S10 
and S12)(9). We included the super-population and the logit population allele frequency as 
covariates. We also included a dummy variable indicating whether or not the variant matched the 
mitochondrial ancestry of the individual carrying the variant. Finally, for the matched and 20 
mismatched groups, we included a separate variable indicating whether or not the variant super-
population matched the nuclear ancestry of the individual who carried the variant.   
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We fitted the model to 768 heteroplasmic variants in 9,179 unrelated matched individuals 
and 30 heteroplasmic variants in 206 unrelated mismatched individuals (9). The heteroplasmic 
variants in the mismatched group were significantly more likely to match the ancestry of the 
nuclear genetic background than the mtDNA background on which the heteroplasmy occurred 
(P=2.9 x 10-4, coefficient estimate=0.85, sd=0.24, logistic regression, Fig. 6D and table S4). 5 
These findings suggest that the new mtDNA variants underwent selection to match the nuclear 
genome. Given the high mutation rate of the mitochondrial genome and the patterns we observed 
over one generation, the selective process is likely to occur within the female germline.  
To independently validate this finding, we repeated this analysis with an additional 40,325 
WGS recruited through the Genomics England 100,000 Genomes Rare Disease Main 10 
Programme (9). There were 36,038 individuals in a haplogroup matched group, 1,098 in a 
haplogroup mismatched group, and 3,124 in a group where the nuclear ancestry could not be 
reliably determined (figs. S12, S13). As before, we focused on the European and Asian specific 
variants observed in 23,931 unrelated European and Asian individuals. We fitted the same 
logistic regression model to 1,942 heteroplasmic variants in 23,277 unrelated matched 15 
individuals, and 67 heteroplasmic variants in 654 unrelated individuals where the nuclear and 
mtDNA had a different ancestral origin. Again, the heteroplasmic variants in the mismatched 
group were more likely to match the ancestry of the nuclear genetic background than the 
ancestral background of the mtDNA on which the heteroplasmy occurred (P=1.33 x 10-3, 
coefficient estimate=0.47, se=0.15, logistic regression, Fig. 6D and table S4). An inverse-20 
weighted meta-analysis of the discovery and validation cohorts yielded a significant association 
across the two datasets (P=3.3 x 10-6, coefficient estimate=0.59, se=0.13). To gain a better 
understanding of underlying mechanisms we studied the gene location and HF of 97 
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heteroplasmic variants identified in the mismatched groups across both the discovery and 
validation studies. Potentially functional variants were found in the non-coding region and RNA 
genes, and also included 14 non-synonymous protein coding variants in the MT-ATP, MT-COX, 
MT-CYB and MT-ND regions (fig. S14). This raises the possibility that differences in oxidative 
phosphorylation and ATP synthesis are responsible the association we observed.   5 
Discussion 
Several explanations have been proposed for the high substitution rate of the non-coding mtDNA 
D-loop, including a high intrinsic mutation rate, and/or a permissive sequence relative to the 
coding regions (31). Here we show that the segregation of mtDNA heteroplasmy likely plays a 
role in shaping D-loop population polymorphisms by a mechanism operating within the female 10 
germline. Similar findings have been seen in Drosophila where D-loop variants ‘selfishly’ drive 
segregation favoring a specific mtDNA genotype (32). These observations have implications for 
the development of mitochondrial transfer techniques for preventing the inheritance of severe 
pathogenic mtDNA mutations in humans (33, 34). After mitochondrial transfer, ~15% of human 
embryonic stem cell lines show reversion to the original mtDNA genotype (34-36). The reasons 15 
for this are not fully understood, but the selective propagation of D-loop heteroplasmy is a 
plausible explanation. Our findings implicate the nuclear genome in this process. This places 
greater emphasis on matching both nuclear and mtDNA backgrounds when selecting potential 
mitochondrial donors, in order to minimize the possibility of nuclear-mitochondrial 
incompatibility following mitochondrial transfer.  20 
In cases of heteroplasmic mtDNA, one allele can be preferentially copied, or segregate to 
high levels in a population of daughter cells. This can lead to changes in mtDNA allele 
frequency during the lifetime of an individual cell, tissue or organism through genetic drift (38, 
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39). A high mtDNA content buffers fluctuations in allele frequency. However, if the number of 
copies falls to a low level, this creates a ‘genetic bottleneck’, increasing the possibility of large 
changes in allele frequency.  
There is a ~1000-fold reduction in cellular mtDNA content during human germ cell 
development (40) is followed by a period of intense proliferation and migration when the germ 5 
cells migrate to form the developing gonad (41). This process is dependent on oxidative 
phosphorylation, and is accompanied by a massive increase in mtDNA levels (40). Under these 
conditions, variants that compromise mitochondrial ATP synthesis will be selected against. On 
the other hand, variants that promote mtDNA replication will have an advantage, potentially 
explaining the preferential transmission of specific D-loop variants. Subtle selective pressures 10 
will have maximal impact at this time, so the nuclear genetic influence we observed will most 
likely come into to play during this critical period of development. Our analysis was based on 
whole-blood DNA, and not a direct analysis of the germ line, so it is possible that tissue-specific 
differences in heteroplasmy come in to play. However, by studying 53,300 mtDNA sequences 
including mother-child pairs, our findings indicate that human mtDNA at the population level is 15 
influenced by selective forces acting within the female germline and modulated by the nuclear 
genetic background. These are apparent within one generation, and ensure consistency between 
these two independent genetic systems, shaping the current world mtDNA phylogeny. 
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Materials and Methods:  
Participants, approvals and sequence acquisition 
The primary data was whole genome sequencing (WGS) from whole-blood DNA from 13,037 
individuals in the NIHR BioResource - Rare Diseases and 100,000 Genomes Project Pilot studies 
(table S5) (22) After quality control (QC, see below and (9)), 12,975 samples including 1,526 5 
mother-offspring pairs were included in this study. For demographics see (9). Ethical approval 
was provided by the East of England Cambridge South national research ethics committee (REC) 
under reference number: 13/EE/0325. WGS was performed using the Illumina TruSeq DNA 
PCR-Free sample preparation kit (Illumina, Inc.) and an Illumina HiSeq 2500 sequencer, 
generating a mean depth of 45x (range from 34x to 72x) and greater than 15x for at least 95% of 10 
the reference human genome (fig. S8A).  
Extracting mitochondrial sequences, quality control and variant detection 
WGS reads were aligned to the Genome Reference Consortium human genome build 37 
(GRCh37) using Isaac Genome Alignment Software (version 01.14; Illumina, Inc.). Reads 
aligning to the mitochondrial genome were extracted from each BAM file and analyzed using    15 
MToolBox (v1.0) (8, 9). Variant Call Files and the merged VCF were normalized with bcftools 
and vt (44, 45, 46), and duplicated variants were dropped with vt. The final VCF was annotated 
using the Variant Effect Predictor (VEP) (47). Further QC was carried out as described (9). 
Potential DNA cross-contamination was investigated using verifyBamID (48) in the nuclear 
genome, and mtDNA variant calls (9). 20 
 
Determining matched and mismatched groups 
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The pairwise relatedness and nuclear ancestry were estimated using nuclear genetic markers as 
described (9). MtDNA haplogroup assignment was performed using HaploGrep2 (27, 57). We 
then compared the mtDNA phylogenetic haplogroup with the nuclear genetic ancestry in the 
same individual, and identified three distinct groups of individuals as described in the text.  
 5 
Defining novel variants  
Variants were considered to be novel if absent from 1000 Genomes datasets and dbSNP and 
were seen in at most one individual amongst 30,506 NCBI mtDNA sequences (5).  
 
MtDNA mutational spectra and signature 10 
Mutational spectra were derived from the reference and alternative alleles as described (25, 58). 
 
Probability of maternal mtDNA transmission 
We modelled the probability of transmission of heteroplasmic variants observed in the mothers 
using the following logistic regression model: 15 logit 𝑃 𝑦!"# = 1 = 𝛼 + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛾𝑤!"# + 𝜂𝑧!"# 
where 𝑦!"# = 1 if the lth variant within mitochondrial genomic region j in mother i was 
transmitted and zero otherwise; 𝑗 = 0, 1, 2, 3 or 4 denote the coding, Dloop, rRNA, tRNA and 
the remainder sequences, respectively; 𝑤!"# is the logit of the HF of the lth variant within 
mitochondrial genomic region j in mother i; and 𝑧!"# = 1 if the lth variant within mitochondrial 
genomic region j in mother i was observed in no individuals from the 1000 Genomes datasets, 20 




Homoplasmic allele frequency in the population and heteroplasmic variants 
We fitted a logistic regression model to explore the relationship between the homoplasmic allele 
frequency in the general population and the rate at which individuals who are not homoplasmic 
for the alternate allele are heteroplasmic (9). 5 
 
Defining haplogroup specific variants on mtDNA phylogenetic tree  
We extracted 4,476 SNVs present on mtDNA phylogenetic tree (27), then focused on SNVs 
either present in only one super-population (European, Asian or African), or present on two 
super-populations but commonly seen in one population (>1%) and not seen or extremely rare in 10 
the other population in 17,520 mtDNAs (5). This defined 2,641 haplogroup-specific variants, 
including 426 African variants, 1,275 Asian variants and 940 European variants.  
 
Nuclear genome ancestry and mtDNA heteroplasmic variants 
We modelled the presence or absence of a heteroplasmic variant in a particular individual using 15 
logistic regression. We considered only the 2,215 mtDNA variants from of over 4,000 
haplogroup-specific variants that are present exclusively in European or Asian branches of the 
world mtDNA phylogeny (27), as this allows unambiguous assignation of mitochondrial ancestry 
to each variant. To avoid the potential for bias induced by recent shared ancestry between 
individuals, we considered only the 9,631 unrelated individuals in matched and mismatched 20 
groups. We fitted the following logistic regression model: logit 𝑃 𝑦!" = 1 = 𝛼 + 𝛽!𝟏𝒙𝒋!𝟏 + 𝛽!𝟏𝒙𝒋!𝟐 +  𝛾𝑤! + 𝜂𝟏𝒛𝒊!𝒘𝒊 + 𝜔𝟏𝒙𝒋!𝒘𝒊∩𝒛𝒊!𝒘𝒊 +  𝜓𝟏𝒙𝒋!𝒘𝒊∩𝒛𝒊!𝒘𝒊 
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where 𝑦!" = 1 if variant 𝑗 is heteroplasmic in individual 𝑖, and zero otherwise; 𝑥! =0, 1 or 2 depending on whether the variant ancestry is Asian, African or European, respectively; 𝑤!is the logit of the homoplasmic allele frequency of variant j in 30,506 NCBI samples; 𝑧! = 0, 1 or 2 depending on whether the mitochondrial ancestry of individual i is Asian, African 
or European, respectively; and 𝑤! = 0, 1 or 2 depending on whether the nuclear ancestry of 5 
individual i is Asian, African or European, respectively. The indicator variable 1 evaluates to 1 if 
the conditions in its subscript are met and zero otherwise.  
 
Validation dataset   
We repeated the nuclear-mtDNA ancestry analysis in 42,799 WGS from whole-blood DNA in 10 
the Genomics England 100,000 Genomes Rare Disease Main Programme aligned to GRCh37 
or/and hg38 using the same bioinformatics pipeline. See (9) for details.   
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(BPD: EGAD00001004519, CSVD: EGAD00001004513, HCM: EGAD00001004514, ICP: 
EGAD00001004515, IRD: EGAD00001004520, MPMT: EGAD00001004521, NDD: 
EGAD00001004522, NPD: EGAD00001004516, PAH: EGAD00001004525, PID: 
EGAD00001004523, PMG: EGAD00001004517, SMD: EGAD00001004524, SRNS: 
EGAD00001004518, See Table S5 for the disease abbreviations). Whole genome sequence data 5 
from the UK Biobank samples are available through a data release process overseen by UK 
Biobank (https://www.ukbiobank.ac.uk/). Whole genome sequence data from the participants 
enrolled in 100,000 Genomes Project can be accessed via Genomics England Limited following 
the procedure outlined at: https://www.genomicsengland.co.uk/about-gecip/joining-research-
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Fig 1. Circos plot of mitochondrial heteroplasmic variants identified in 1,526 mother-
offspring pairs.  
Circles from the outside to the inside indicate the following: (1) position of a variant on the 
mtDNA, the removed regions are shown in red crosses; (2) Minor allele frequency for common 
variants (MAF>1%) derived from 30,506 NCBI mtDNA sequences (5), where the radial axis 5 
corresponds to the MAF; (3) phastCons100way scores from UCSC (42) where the radial axis 
corresponds to the degree of conservation ; (4) heteroplasmic variants identified in the mothers 
where the radial axis corresponds to the heteroplasmy fraction, HF; (5) regions corresponding to 
the different mtDNA genes (yellow - D-loop, purple – coding region, green – rRNAs and orange 
- tRNAs); (6) heteroplasmic variants identified in the offspring where the radial axis corresponds 10 





Fig 2. Transmission of heteroplasmic mtDNA variants in 1,562 mother-offspring pairs.  
(A) Frequency distribution of number of heteroplasmic variants in the mothers and offspring. (B) 
Distribution of HF in the mothers and offspring, transmitted, inherited, lost and de novo are 
shown separately. (C) Scatter plot of logit(HF) in transmitted heteroplasmic variants between the 
mothers and offspring (R2=0.79, P=1.52 x 10-93, Pearson's correlation). (D) Left, difference in the 5 
percentage shift of HF between the offspring and the corresponding mothers (HFoffspring - 
HFmother) ordered by the degree of shift. Right, distribution of the difference of the percentage 
shift of HF between offspring and the corresponding mothers (HFoffspring - HFmother). (E) 
Left, log2 ratio of HF difference between offspring and the corresponding mothers ordered by 
the degree of log2 ratio. Three increase HSs with values above 6 shown in the box. Right, 10 
distribution of log2 ratio of HF difference between offspring and the corresponding mothers. (F) 
log2 ratio of HF difference between offspring and the corresponding mothers aligned to the 
whole mitochondrial DNA sequence; the mtDNA regions are shown at the bottom bar in 





Fig 3. Characteristics of the heteroplasmic mtDNA variants in 1,562 mother-offspring 
pairs.  
(A) Mutation rate of mtDNA genomic regions was estimated using 477 de novo heteroplasmic 
variants from 1,526 mother-offspring pairs detected at HF>1%. Vertical axes represent 
1/log2(mutation rate) per base per mother-child transmission. mtDNA genomic regions are 5 
labeled and shown in different colors (yellow - D-loop, purple – coding region, green – rRNAs 
and orange - tRNAs). All tRNAs were combined to estimate the tRNA mutation rate. Note that 
this is the raw number of new mutations/bp/transmission detected at HF>1% in the offspring, 
and does not factor in the detection threshold nor segregation because current models assume 
neutrality(13, 43), which we later show is not the case. (B) Pathogenic mutations were observed 10 
in 1,526 mother-offspring pairs. Each dot represents the HF in the mothers (blue) and the 
corresponding offspring (pink); the directions of arrow show increase (->) or decrease (<-) HS; 
the length of the arrow between each pair of points represents the change in HF (orange - 
transmitted heteroplasmic variants, grey - de novo / lost heteroplasmic variants). (C) Frequency 
of heteroplasmic variants at CpG and non-CpG islands. Expected, homplasmic variants, 15 
transmitted, lost and de novo heteroplasmic variants are shown separately. (D) Number of novel 
versus known heteroplasmic variants in transmitted, lost and de novo heteroplasmic variants, 
increase and decreasing HS in transmitted heteroplasmic variants are shown in different colors. 
(E) Distribution of HS between the offspring and the corresponding mothers in transmitted 
known and novel heteroplasmic variants, increase and decreasing HS are shown in different 20 
colors. (F) Frequency of haplogroup defining variants in transmitted, lost and de novo 
heteroplasmic variants. The transmitted heteroplasmic variants were more likely to affect known 
haplogroup specific sites on the world mtDNA phylogeny than the lost and de novo 
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heteroplasmic variants (P=7.86 x 10-11 and P=0.0016 respectively, Fisher’s exact test). P value < 




Fig 4. Evidence of selection during the transmission of mtDNA heteroplasmy in 1,526 
mother-offspring pairs.  
(A) Cumulative distributions of HF in the mothers and offspring within each mtDNA region. 
Vertical lines between two curves show the greatest distance between Dloop / SS and NS / rRNA 
/ tRNA regions (P-values in table S3). (B) NS/SS ratio of NS and SS variants for observed 5 
homoplasmic polymorphisms, total heteroplasmic variants, transmitted, lost and de novo 
heteroplasmic variants. (C) Frequency of heteroplasmic variants affecting conserved and non-
conserved sites. Expected, homoplasmic variants, transmitted, lost, de novo heteroplasmic 
variants, increase and decrease HSs are shown separately. (D) Number of heteroplasmies 
showing an increase or decrease HF in each mtDNA region. Left-facing arrows indicate that the 10 
number increasing was less than the number decreasing. Right-facing arrows indicate that the 
number increasing was greater than the number decreasing. (E) Histograms of HS in each 
mtDNA region with fitted kernel density curves. (F) Bar plot of the frequency of transmitted 
heteroplasmic variants by bins of HF in the mothers. (G) Frequency of transmitted heteroplasmic 
variants in each mtDNA region, along with 95% confidence intervals. (H) Receiver operating 15 
characteristic (ROC) curve for the logistic regression model of transmission (Area under the 





Fig 5. The distribution of heteroplasmic variants in mtDNA Dloop region.  
(A) MAF of homoplasmic single nucleotide polymorphisms observed in 30,506 NCBI mtDNA 
sequences, with an expanded axis to show MAF<10% at the bottom. (B) Trend of PhastCons 
scores is shown across the mtDNA D-loop region. (C) HFs observed in 12,975 mtDNA 
sequences in the D-loop region. MT-TAS2 and MT-CSB1 are shadowed in light purple. MT-5 
LSP is shadowed in light orange. Corresponding known sub-regions of the mtDNA D-loop are 
shown at the bottom. Key - MT-3H: mt3 H-strand control element, MT-3L: L-strand control 
element, MT-4H: mt4 H-strand control element, MT-7SDNA: 7S DNA, MT-CSB1: Conserved 
sequence block 1, MT-CSB2: Conserved sequence block 2, MT-CSB3: Conserved sequence 
block 3, MT-HPR: replication primer, MT-HSP1: Major H-strand promoter, MT-HV1: 10 
Hypervariable segment 1, MT-HV2: Hypervariable segment 2, MT-HV3: Hypervariable 
segment 3, MT-LSP: L-strand promoter, MT-OHR: H-strand origins, MT-OHR57: H-strand 
origin, MT-TAS: termination-associated sequence, MT-TAS2: extended termination-associated 
sequence, MT-TFH/MT-TFL/ MT-TFX/ MT-TFY/: mtTF1 binding site. (D) Trinucleotide 
mutational signature of heteroplasmic variants in the D-loop region in 12,975 mtDNA sequences. 15 
The bars representing the frequency for the six types of substitution are displayed in different 
colours. Labeled heteroplasmic variants are included in the bars with the red circles. (E) 
Simplified mtDNA phylogeny tree showing 6 heteroplasmic variants (refer to main text). 
Variants are shown in red and haplogroups are shown in blue. The pie chart sizes are 
proportional to the number of samples (shown at the bottom) belonging to the corresponding 20 
haplogroup in 10,210 unrelated mtDNA sequences. The proportion of samples carrying each 
heteroplasmic variant within the same haplogroup is shown in yellow. (F) HF of six 




Fig 6. The characteristics of heteroplasmic variants in the nuclear ancestry and mtDNA 
ancestry matched and mismatched groups.  
 (A) Schematic showing how individuals with matched (MG, red border) and mismatched 
(MMG, green border) nuclear and mtDNA genomes arise over generations. Red and grey 
colored mtDNAs represent two different hypothetical populations. (B) I. Projection of the 5 
nuclear genotypes at common SNPs onto the two leading principal components computed with 
the 1000 Genomes dataset, with individuals colored by their assigned nuclear ancestry: Asian 
(blue), African (green), European (red) and Other (orange). The individuals colored in blue, 
green and red in the boxes labelled II, III and IV are shown in panels II, III and IV, respectively, 
where they are colored by their mitochondrial ancestries. Stars indicate that the mitochondrial 10 
ancestry does not match the nuclear ancestry. (C) Proportion of haplogroup defining variants in 
the matched group (MG) and mismatched group (MMG) in 9,631 mtDNA sequences from 
unrelated individuals, along with the expected proportion shown at the left side. Distinct 
heteroplasmic sites were more likely to affect known haplogroup specific sites (26) than the rest 
of the mitochondrial genome compared to that expected by chance (P<2.2 x 10-16, Fisher’s exact 15 
test). This bias was stronger in the mismatched group than the matched group (P=0.001, Fisher’s 
exact test). (D) Heatmaps showing the density of observed heteroplasmic mtDNA haplogroup-
defining variants in the observation dataset (left) and validation dataset (right). The matched 
(top) and mismatched (bottom) groups are shown separately, broken down by the nuclear 
ancestry of the carrier and the major haplogroup of the variants. The width of each column is 20 
proportional to the number of variants defining each of the two major haplogroups (Asian and 
European). Within each heatmap, the height of each row is proportional to the number of 
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individuals having each nuclear ancestry. The density of heteroplasmic variants in each cell 
determines its color. 
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Other Supplementary Materials for this manuscript include the following:  5 
 
Data S1. List of heteroplasmic variants detected in 1,526 mother-offspring pairs 





Materials and Methods  
Study samples 
Our primary data source was whole genome sequencing (WGS) data from whole-blood 
DNA from 13,037 individuals in the NIHR BioResource - Rare Diseases and 100,000 Genomes 
Project Pilot studies, including the patients affected by rare diseases and their relatives across 5 
several different disease domains (All the individuals are also included (table S5) (22). After 
quality control (QC) (details below), 12,975 samples including 1,526 mother-offspring pairs 
were included in this study. The ages of the mothers at sample collection ranged from 22 to 95 y 
(88 missing), the ages of the mothers at the time of giving birth ranged from 16 to 54 y (at least 




Ethical approval was provided by the East of England Cambridge South national research 
ethics committee (REC) under reference number: 13/EE/0325, with the majority of UK 15 
participants providing written informed consent for this approved study. Some UK participants 
were consented under an alternative REC-approved study obtained by the local investigators. 
Consent for non-UK samples was the responsibility of the respective principal investigators at 
the enrolling hospitals. 
 20 
Extracting mitochondrial sequences and detecting variants  
WGS was performed using the Illumina TruSeq DNA PCR-Free sample preparation kit 
(Illumina, Inc.) and an Illumina HiSeq 2500 sequencer, generating a mean depth of 45x (range 
from 34x to 72x) and greater than 15x for at least 95% of the reference human genome (fig. 
S8A). 25 
 
The WGS reads were aligned to the Genome Reference Consortium human genome build 37 
(GRCh37) using Isaac Genome Alignment Software (version 01.14; Illumina, Inc.) with options 
--cleanup-intermediary 1 --memory-limit 123 --base-quality-cutoff 15 --gap-scoring bwa --
variable-read-length yes --ignore-missing-bcls 1 --ignore-missing-filters 1 --split-gap-length 30 
10000 --per-tile-tls 1  --use-bases-mask Y150N1,Y150N1 --tiles s_4 --base-calls-format bcl-gz. 
The subset of sequencing reads which aligned to the mitochondrial genome were extracted from 
each sample’s BAM file. We then ran MToolBox (v1.0) on the resulting smaller BAM files 
using the options mtdb_fasta=chrMT.fa, hg19_fasta=hg19RCRS.fa, mtdb=chrM, 
humandb=hg19RCRS, ref=RCRS, UseMarkDuplicates=true, UseIndelRealigner=true and 35 
MitoExtraction=true (8). MToolBox realigns the reads with GSNAP, which outputs multiple 
alignments per read up to a certain penalty score. It then uses mapExome.py to discard any read 
pairs for which either of the two reads in the pair mapped to multiple locations, including, for 
example, nuclear mitochondrial sequences in the nuclear genome and amplification artifacts. The 
VCFs were individually normalised and merged across all samples with bcftools (44, 45). The 40 
merged VCF was re-normalised with bcftools and vt (46) and duplicated variants were dropped 
with vt. The final VCF was annotated using the Variant Effect Predictor (VEP) (47). 
 
Quality control of samples 
Firstly, potential DNA cross-contamination was investigated using the nuclear genome. All 45 





samples passed contamination quality checks conducted by the sequencing provider Illumina, 
Inc. Additionally, we estimated the degree to which a DNA sample was contaminated by any 
other DNA sample using verifyBamID (48). Samples with an estimate of contamination 
(FREEMIX) exceeding 3% were excluded. The median FREEMIX value of the 13,037 samples 
included in the study was 0.042% and 99.84% of the samples had a FREEMIX value smaller 5 
than 1%.  
 
Potential DNA cross-contamination was also checked using mtDNA variant calls. Samples 
carrying more than 20 heteroplasmic variants with HF >2% or carrying more than 5 
heteroplasmies with similar HFs defining alternative haplogroups were excluded from this study. 10 
Additionally, we removed samples with the mean depth of the mtDNA genome < 200x. These 
QC checks removed 62 samples from the initial 13,037 mtDNA sequences. 12,975 individuals 
including 1,526 mother-offspring pairs were included to perform the analyses. We did not find 
an association between the logit (FREEMIX) parameter and presence of at least one 
mitochondrial heteroplasmy (P=0.89, logistic regression), further indicating that heteroplasmic 15 
calls were unlikely to be due to cross-sample contamination. 
 
Quality control of variants 
To define heteroplasmic variants, we selected variants as follows: 1) retain variants for 
which the confidence interval of VAF overlaps the range 1% to 98%; 2) remove all indels, as 20 
detecting heteroplasmic indels is unreliable using short-read sequencing data; 3) remove variants 
at sites with multiple alternate alleles, all of which have HFs < 5%; 4) remove variants falling 
within specific regions associated with misalignment errors related to homopolymeric tracts (np 
66-71, 300-316, 513-525, 3106-3107, 12418-12425 and 16182-16194) (49); 5) remove 
heteroplasmic variants present in more than 2% of the individuals but not reported or vary rare in 25 
heteroplasmic variants in the literature (14) and 1000 Genomes individuals (np 499, 538, 545, 
10953 and 12684); 6) remove variants less than 2 reads on each strand with the minor allele; 7) 
remove heteroplasmic variants with depth < 200x and low level heteroplasmies (HFs<5%) with 
depth < 500x, unless a Bonferroni-corrected p-value < 10-5 was given by deepSNV (10, 11). 
Specifically, we used deepSNV to compare the nucleotide counts at a putative heteroplasmic 30 
variant site in a sample with a random set of 500 other unrelated samples using a beta-binomial 
model, to further reduce the false positive calls which were caused by the NUMTs and the 
sequencing error. 
 
Validating heteroplasmic variants - duplicates 35 
In order to validate the reliability of variant calling in this study, we assessed 22 samples 
sequenced twice independently. The concordance of homoplasmic variants between duplicates 
was 100%. We further assessed the consistency of heteroplasmic variant calls. After quality 
control, there were 28 heteroplasmic variants with the confidence interval of VAF between 1% 
and 98% detected in 20 duplicates (40 samples) using MtoolBox. Only one of these variants, 40 
with a HF of 2.1%, was present in only one of the duplicates, giving an overall concordance of 
96.4%. The deepSNV-based filter removed 6 non-concordant heteroplasmic calls with HF <3% 
(fig. S2). The implications of the duplicate analysis suggested the high accuracy of our analysis 
pipeline to detect the low level heteroplasmies. 
 45 
Classifying the heteroplasmic variants 





We defined three categories of heteroplasmy: (1) transmitted/inherited, if the variant was 
present in the mother and the offspring and was heteroplasmic in at least one of the two; (2) lost, 
if the heteroplasmic variant was present in the mother but not detected in the offspring; and (3) 
de novo, if the heteroplasmic variant was present in the offspring and not detected in the mother 
(table S1 and Data S1). Note that lost variants can be present in maternal blood but absent from 5 
the germ line. For the lost and de novo heteroplasmies, they are likely present in offspring (lost 
heteroplasmies) or mothers (de novo heteroplasmies) with very low level of heteroplasmic 
fraction (HF < 1%) which are below our detection threshold. 
 
We studied the log2 ratio of HF between offspring and mothers after imputation of HF 10 
values below 1% to our detection threshold of 1%. Heteroplasmic variants with a 
positive/negative HS were deemed to have an increasing/decreasing HS over one generation. We 
further classified the heteroplasmic variants into two categories: (1) increasing HS, where the 
log2 ratio of HF between offspring and mothers > 0; (2) decreasing HS: where the log2 ratio of 
HF between offspring and mothers < 0.  15 
 
Estimation of pairwise relatedness and nuclear ancestry 
We estimated the degree of relatedness between individuals and categorised each 
individual's nuclear ancestry into one of European, African, Asian or Other using genotype data 
from a set of SNPs selected as follows. We identified the 292,878 autosomal SNPs typed by 20 
three widely used Illumina genotyping arrays (HumanCoreExome-12v1.1, HumanCoreExome-
24v1.0 and HumanOmni2.5-8v1.1). Presence of a SNP in all three arrays indicates that it can be 
reliably measured by microarray and, hence, that it is likely to be reliably called using whole 
genome sequencing as well. To further ensure this, we removed SNPs with a missing genotype 
in at least one individual or with an overall pass rate below 0.99. We also removed SNPs at 25 
genomic positions in which more than two distinct alleles had been observed in the 1000 
Genomes Phase 3 dataset (50) or the NIHR BioResource dataset to ensure that all genotypes 
could be coded unambiguously in as a count of the number of copies of the unique alternative 
allele carried by the individual. We then removed SNPs with a MAF < 0.3 in our dataset. Finally, 
we pruned SNPs using PLINK (v1.9) ( http://pngu.mgh.harvard.edu/purcell/plink/) (51) so that 30 
all pairs of SNPs had an r2 < 0.2. After filtering, 32,875 SNPs remained. 
 
These well-measured, unlinked common SNPs were used to estimate relatedness in the non-
admixed individuals within the 1000 Genomes Phase 3 data as follows. First, we ran the KING R 
package to compute an initial kinship matrix and identify a corresponding initial set of unrelated 35 
individuals (52, 53). We then used PC-AiR (54, 55) to perform a principal component analysis 
(PCA) on the standardised genotypes of these putatively unrelated individuals and project the 
standardised genotypes of the other individuals onto the fitted principal components (PCs). The 
PC-AiR object was then passed to the PC-Relate function to compute a kinship matrix that 
accounts for population structure as represented by the leading 20 PCs (54). Finally, the kinship 40 
matrix was passed to the PRIMUS (56) function to obtain a final set family relations and a final 
set of unrelated individuals based on kinship coefficients > 0.09. 
 
We partitioned these unrelated individuals as non-Finnish Europeans, Finns, Africans, 
South Asians and East Asians using their 1000 Genomes population code annotations. Within 45 
each element of this partition, we modelled the score vectors of the leading five principal 





components by a multivariate normal distribution and estimated the corresponding mean vectors 
and covariance matrices. Subsequently, we projected the genotypes from each of the NIHR 
BioResource samples onto the vector space spanned by the leading five components of the 1000 
Genomes PCA. We computed the likelihood of the projected data under the five multivariate 
normal models estimated from the 1000 Genomes scores and labelled the individual with the 5 
population corresponding to the model that yielded the highest likelihood, provided it was 
greater than 2000. Otherwise, the individual was labelled "Other." For the purposes of this work, 
we did not require distinguishing between non-Finnish Europeans and Finns because they share 
the same mitochondrial haplogroups. We therefore recorded only the greatest likelihood among 
the two populations and labelled it simply "European". For the same reason, we also recorded 10 
only the highest likelihood amongst East and South Asians and labelled it “Asian”. Finally, in 
order to exclude individuals with recent ancestry from more than one population (admixture), 
samples for which the model with the greatest likelihood was less than 1010 times greater than 
the model with the second greatest likelihood were labelled "Other". 
 15 
To compute the relatedness within the new sequence dataset, the genotypes were merged 
with the 1000 Genomes genotypes and the procedure described above to compute relatedness 
was followed a second time. As the 1000 Genomes collection is genetically diverse by design, 
combining the two datasets ensured that a greater amount of genetic diversity was accounted for 
by the PCA than if only the new sequence dataset had been used. The PC-Relate estimates of the 20 
genome proportions shared by zero, one and two chromosomes between two individuals were 
used to categorise pairwise relations, identify mother-offspring pairs and the set of 10,210 
unrelated individuals for the purposes of this work. The relatedness for all the mother and 
offspring pairs was further confirmed by the gender, age and the mitochondrial haplogroups. All 
the mother-offspring pairs shared the same mtDNA haplogroups.  25 
 
Determining matched and mismatched groups  
Mitochondrial DNA haplogroup assignment was performed using HaploGrep2 (27, 57). We 
compared the mtDNA phylogenetic haplogroup with the nuclear genetic ancestry in the same 
individual, and identified three distinct groups of individuals: (1) a haplogroup matched group 30 
where the mtDNA haplogroup was concordant with the nuclear ancestry; (2) a mismatched 
group where the nuclear ancestry and mtDNA were from different human populations, and (3) a 
final group where the nuclear ancestry could not be reliably determined (Fig. 6, A and B and 
fig. S10). In this particular analysis, we further excluded 42 out of the 12,975 samples because 
they had low haplogroup prediction scores as follows: 1) haplogroup prediction score below 0.8 35 
in non-haplogroup H individuals, 2) haplogroup prediction score below 0.5 in haplogroup H and 
sub-haplogroup individuals. Because Haplogrep2 uses rCRS as the reference genome, which 
belongs to European haplogroup H (49), very few haplogroup specific variants were needed to 
predict the same haplogroup. Subsequent analyses focused on the haplogroup matched and 
mismatched groups. 40 
 
Defining known and novel variants  
Variants were considered to be novel if they were absent from 1000 Genomes datasets and 
dbSNP and were seen in at most one individual amongst 30,506 NCBI mtDNA sequences (5). 
The frequency of variants in 1000 Genomes and dbSNP was extracted using MToolBox (8). The 45 
allele frequencies in 30, 506 NCBI mtDNA sequences were computed in previous work (5).  







Mutational spectra and signature 
Mutational spectra were derived from the rCRS reference and alternative alleles at each 
variant site. The resulting spectra were composed of the relative frequencies of the six 5 
distinguishable point mutations (C:G>T:A, T:A>C:G, C:G>A:T, C:G>G:C, T:A>A:T and 
T:A>G:T). Each signature was displayed using a 96 substitution classification defined by the 
substitution class and the sequence context immediately 3’ and 5’ of the mutated base (25, 58). 
 
Conservation scores 10 
PhastCons100way scores for the mtDNA genome were downloaded from UCSC (42). We 
defined as conserved sites those with a PhastCons100way score >0.5, and the non-conserved 
sites as those with a PhastCons100way score <0.5. We estimated the number of expected 
conserved/non-conserved sites as the number of base pairs in the entire mtDNA genome with a 
PhaseCons 100 score above/below 0.5.  15 
 
Probability of maternal mtDNA transmission 
In order to understand the determinants of maternal transmission of heteroplasmic variants, 
we are modelling the probability of transmission of 1,043 heteroplasmic variants observed in the 
mothers using the following logistic regression model: 20 
 logit 𝑃 𝑦!"# = 1 = 𝛼 + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛽!𝟏!!! + 𝛾𝑤!"# + 𝜂𝑧!"# 
 
where 𝑦!"# = 1 if the lth variant within mitochondrial genomic region j in mother i was 
transmitted and zero otherwise; 𝑗 = 0, 1, 2, 3 or 4 denote the coding, Dloop, rRNA, tRNA and 
the remainder sequences, respectively; 𝑤!"# is the logit of the HF of the lth variant within 25 
mitochondrial genomic region j in mother i; and 𝑧!"# = 1 if the lth variant within mitochondrial 
genomic region j in mother i was observed in no individuals from the 1000 Genomes datasets, 
dbSNP and at most one individual amongst 30,506 NCBI mtDNAs, otherwise it was equal to 
zero. The model was fitted using the glm() function in R(v3.3) (http://CRAN.R-project.org/). 
The predictive accuracy was assessed using the mean area under the curve over repeated 10-fold 30 
cross-validations obtained using R. 
 
Homoplasmic allele frequency in the population and heteroplasmic variants 
To explore the relationship between the homoplasmic allele frequency in the general 
population and the rate at which individuals who are not homoplasmic for the alternate allele are 35 
heteroplasmic, we fitted a logistic regression model as follows. For each variant observed in 
30,506 NCBI sequences and individual who was not homoplasmic for the alternate allele, we 
recorded whether the individual was heteroplasmic or not as a binary variable. We then fitted a 
logistic regression model with an intercept and a single continuous covariate encoding the logit 
of the allele frequency in 30,506 NCBI sequences. 40 
 
Defining haplogroup specific variants on mtDNA phylogenetic tree  
We extracted 4,476 SNVs present on mtDNA phylogenetic tree (27) using in-house python 
scripts. We then focused on SNVs either present in only one super-population (European, Asian 
or African) on the phylogenetic tree, or present on two super-population, but were commonly 45 





seen in one population (>1%) and not seen or extremely rare in the other population in 17,520 
full mtDNA sequences from NCBI database (5). We defined 2,641 haplogroup-specific variants, 
including 426 African variants, 1,275 Asian variants and 940 European variants.  
 
Nuclear genome ancestry and mtDNA heteroplasmic variants 5 
In order to understand the determinants of heteroplasmic variation, we modelled the 
presence or absence of a heteroplasmic variant in a particular individual using logistic regression. 
We considered only the 2,215 mtDNA variants from of over 4,000 haplogroup-specific variants 
that are present exclusively in European or Asian branches of the world mtDNA phylogeny (27), 
as this allows unambiguous assignation of mitochondrial ancestry to each variant. To avoid the 10 
potential for bias induced by recent shared ancestry between individuals, we considered only the 
9,631 unrelated individuals in matched and mismatched groups. We fitted the following logistic 
regression model: 
 logit 𝑃 𝑦!" = 1 = 𝛼 + 𝛽!𝟏𝒙𝒋!𝟏 + 𝛽!𝟏𝒙𝒋!𝟐 +  𝛾𝑤! + 𝜂𝟏𝒛𝒊!𝒘𝒊 + 𝜔𝟏𝒙𝒋!𝒘𝒊∩𝒛𝒊!𝒘𝒊 +  𝜓𝟏𝒙𝒋!𝒘𝒊∩𝒛𝒊!𝒘𝒊 
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where 𝑦!" = 1 if variant 𝑗 is heteroplasmic in individual 𝑖, and zero otherwise; 𝑥! =0, 1 or 2 depending on whether the variant ancestry is Asian, African or European, respectively; 𝑤!is the logit of the homoplasmic allele frequency of variant j in 30,506 NCBI samples; 𝑧! = 0, 1 or 2 depending on whether the mitochondrial ancestry of individual i is Asian, African 
or European, respectively; and 𝑤! = 0, 1 or 2 depending on whether the nuclear ancestry of 20 
individual i is Asian, African or European, respectively. The indicator variable 1 evaluates to 1 if 
the conditions in its subscript are met and zero otherwise. The model was fitted using the glm() 
function in R. 
 
Validation dataset   25 
We repeated the nuclear-mtDNA ancestry analysis in 42,799 WGS from whole-blood 
samples from the Genomics England 100,000 Genomes Rare Disease Main Programme aligned 
to GRCh37 or/and hg38. The same bioinformatic pipeline was used to call mtDNA variants as in 
the observation dataset (see above). 40,325 mtDNA sequences had mtDNA coverage > 99.9%, 
mean depth > 500x, no more than 20 heteroplasmies and an accurate prediction of mtDNA 30 
ancestry (see above) and were thus retained for analysis. The mean depth of WGS was 42x 
(range 29x to 121x) and the mean depth of mtDNA was 1919x (range 500x to 7458x) (fig S15).  
        To infer ethnicity and relatedness in this dataset, we lifted over our original list of common 
SNPs from GRCh37 to GRCh38 using the liftOver tool from the UCSC web browser 
(https://genome.ucsc.edu/cgi-bin/hgLiftOver). During this conversion 210 SNPs were lost: 1) 17 35 
SNPs because their positions could not be mapped to GRCh38, 2) 134 SNPs because the 
reference and alternate alleles had been swapped, 3) 42 SNPs because they were missing from 
the GRCh38 1000G VCF, 4) 17 because their AFs in Europeans were discrepant between the 
observation and the validation datasets. We then ran the same code as described above but using 
the list of 32,665 SNPs on GRCh38.  40 
        We implemented a custom heuristic procedure to identify the maximal unrelated set, instead 
of using PRIMUS, as PRIMUS was computationally unable to cope with such a large dataset. 
The procedure iteratively removes the individual with the greatest number of relatives (defined 
as individuals with a kinship coefficient >0.09) until there are no relatives remaining. To boost 
power, we maximised the number of mismatched individuals in our unrelated set as follows. 45 





First, we identified the maximum unrelated set amongst mismatched individuals. We then 
combined this set with all matched individuals and re-ran the heuristic approach to obtain a final 
set of unrelated individuals. 
 
Statistical analysis 5 
All statistical analyses in this study were suggested in the text and performed using R (v3.3) 
(http://CRAN.R-project.org/). Circos plots were made using Circos (59). Figures were generated 
using Matplotlib (https://matplotlib.org) in Python (http://www.python.org) and R.   
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Fig. S1. Sequencing coverage and depth. (A) Box-whisker plots of mean coverage of mtDNA 
genome in 1,526 mother-offspring pairs. (B) Box-whisker plots of mean read depth of mtDNA 
genome in 1,526 mother-offspring pairs. There was no significant difference between the 5 
mtDNA sequence depth of mother and offspring (P=0.49, two sample t-test).  






Fig. S2. Reproducibility of the heteroplasmy calling pipeline. We assessed 22 samples 
sequenced independently on two occasions. After quality control, there were 28 heteroplasmic 
variants with the confidence interval of VAF between 1% and 98% detected in 20 duplicates (40 
samples) using MtoolBox. Only one of these variants, with a HF of 2.1%, was present in only 5 
one of the duplicates, giving an overall concordance of 96.4%. The deepSNV-based filter 
removed 6 non-concordant heteroplasmic calls with HF <3%. Red “X” represents the 
heteroplasmic variants called by MTool box, and blue “+”represents the heteroplasmic variants 
further filtered using deepSNV.   





            
Fig. S3. Correlation of number of heteroplasmic variants in the mothers and the age of the 
mothers (R2=0.17, P=6.42 x 10-11, Pearson's correlation). The distributions of mother’s ages and 
number of heteroplasmic variants are shown at the top and right side.  







Fig. S4. Read alignment views at mtDNA position 57. Top, offspring carrying 57 T>C variant; 
bottom, the corresponding mother carrying 57 T allele. The mother and offspring belonged to the 
same mtDNA sub-haplogroup, excluding a sample mix-up.  5 







Fig. S5. Read alignment views at mtDNA position 8993. Top, offspring carrying 8993 T>G 
variant; bottom, the corresponding mother carrying 8993T allele. The mother and offspring 
belonged to the same mtDNA sub-haplogroup, excluding a sample mix-up.  5 







Fig. S6. Read alignment views at mtDNA position 14459. Top, offspring carrying 14459 G>A 
mutation; bottom, the corresponding mother carrying 14459G allele. The mother and offspring 
belonged to the same mtDNA sub-haplogroup, excluding a sample mix-up.  5 






Fig. S7. Trinucleotide mutational signatures. (A) Trinucleotide mutational signatures of 
polymorphisms in 30,506 NCBI mtDNA sequences. (B) Trinucleotide mutational signatures of 
polymorphisms in 1,526 mother offspring pairs. (C) Trinucleotide mutational signatures of 
transmitted/inherited (the first two plots), lost and de novo heteroplasmic variants in 1,526 5 





mother offspring pairs. HFs of the mothers are shown in the transmitted and lost trinucleotide 
mutational signatures. HFs of the offspring are shown in the inherited and de novo trinucleotide 
mutational signatures. The frequency bars for the six types of substitutions are displayed in 
different colours within different colour backgrounds labelled at the top of the graph. The 
trinucleotide signatures are on the horizontal axes at the bottom, and CpG islands are highlighted 5 
in the red rectangles. The frequencies of 96 possible mutation combinations are shown on the left 
side of y- axis, and HFs of the mother and offspring are shown on the right side of y-axis. The 
red triangles represent decrease heteroplasmic variants, and the green triangles represent increase 
heteroplasmic variants.  
10 







Fig. S8. (A) Box-whisker plots of mean depth of whole genome sequence from 12,975 
individuals. (B) Mean depth of whole mitochondrial genome (left) and only D-loop region (right) 
from 12,975 individuals. The middle “box” represents the median, lower and upper quartile of 5 
the data. The upper and lower whiskers represent the data outside the middle 50%. The dots 
represent the data outside 25% - 75% of the data. 
  








Fig. S9. Trinucleotide mutational signatures in 12,975 mtDNA sequences. (A) Trinucleotide 
mutational signatures of homoplasmic variants in 30,506 NCBI mtDNA sequences. (B) 5 
Trinucleotide mutational signatures of heteroplasmic variants in 12,975 mtDNA sequences. 
whole mtDNA genome, D-loop, SS, NS, rRNA and tRNA heteroplasmic variants are shown 
separately. The frequency bars for the six types of substitutions are displayed in different colours 





labelled at the top of the graph. The trinucleotide signatures are on the horizontal axes at the 
bottom. The frequencies of 96 possible mutation combinations are shown on the left side of y- 
axis. 






Fig. S10. Number of subjects in each ethnic group based on the nuclear and mtDNA 
ancestry. The ethnicity predicted using the nuclear genome labeled at the top, the mtDNA major 
haplogroups and the populations defined by mtDNA genome labeled on the left side. Africans in 
the matched group highlighted in green, Asians in blue and Europeans in red. The mismatched 5 
group is shown in the white background. The numbers of unrelated individuals are shown in the 
brackets.  







Fig. S11. (A) Mean number of heteroplasmic variants in the matched and mismatched groups. 
There was no significant difference between two groups (P>0.05, Wilcoxon rank sum test). (B) 
Mean HF in the matched and mismatched groups. There was no significant difference between 5 
two groups (P>0.05, Wilcoxon rank sum test). The error bar represents the standard deviation.   





                
Fig. S12. Number of subjects in each ethnic group based on the nuclear and mtDNA 
ancestry in the validation dataset. The ethnicity predicted using the nuclear genome labeled at 
the top, the mtDNA major haplogroups and the populations defined by mtDNA genome labeled 
on the left side. Africans in the matched group highlighted in green, Asians in blue and 5 
Europeans in red. The mismatched group is shown in the white background. The numbers of 
unrelated individuals are shown in the brackets.  







Fig. S13. Principal component analysis of the validation dataset. I. Projection of the nuclear 
genotypes at common SNPs onto the two leading principal components computed using the 1000 
Genomes dataset, with individuals coloured by their assigned nuclear ancestry: Asian (blue), 5 
African (green), European (red) and Other (orange). The individuals coloured in blue, green and 
red in the boxes labelled II, III and IV are shown in panels II, III and IV, respectively, where 
they are coloured by their mitochondrial ancestries.  





           
Fig. S14. Non-synonymous mtDNA variants found in people with a mis-match between 
their mtDNA and nuclear ancestry where the heteroplasmy matched the nuclear ancestry. 
HF = heteroplasmy fraction (%). X-axis = gene location of the variant.





   
Fig. S15. Left: Box-whisker plots of mean depth of whole genome sequence from 40,325 
individuals in the validation dataset. Right: Mean depth of whole mitochondrial genome from 
40,325 individuals in the validation dataset. The middle “box” represents the median, lower and 
upper quartile of the data. The upper and lower whiskers represent the data outside the middle 5 
50%. The dots represent the data outside 25% - 75% of the data. 
  





Table S1. Summary of the heteroplasmic variants detected in the 1,526 mother-offspring 
pairs. 
 
HF = heteroplasmic fraction (%). 
 5 
 
    
No. of  
individuals 




variant Average HF % (sd) 
Mother   1,526 728 (47.8%) 1,043 11.4 (sd 12.2)  
 Lost   614 (58.8%) 5.6 (sd 6.3) 
 Transmitted   429 (41.2%) 19.5 (sd 13.9) 
Offspring   1,526 648 (42.5%) 893 12.5 (sd13.0)   
 de novo   477 (53.4%) 6.2 (sd 7.4) 
 Inherited   416 (46.7%) 19.8 (sd 14.1) 
Pair     929 (60.9%)    
Total   3,052   1,936   





Table S2. de novo rate in mtDNA genomic regions 
 
 
Locus  Length (bp) 
No. of de 
novo 
de novo 
rate/base/genome 95% CI 
DLOOP 1124 13 7.64E-05 (6.39E-05 - 9.06E-05) 
MT-ATP6 681 19 1.83E-05 (1.10E-05 - 2.86E-05) 
MT-ATP8 207 6 1.90E-05 (6.97E-06 - 4.13E-05) 
MT-CO1 1542 35 1.49E-05 (1.04E-05 - 2.07E-05) 
MT-CO2 684 21 2.01E-05 (1.25E-05 - 3.08E-05) 
MT-CO3 784 17 1.42E-05 (8.28E-06 - 2.28E-05) 
MT-CYB 1141 41 2.35E-05 (1.69E-05 - 3.19E-05) 
MT-ND1 956 20 1.37E-05 (8.37E-06 - 2.12E-05) 
MT-ND2 1042  19 1.19E-05 (7.19E-06 - 1.87E-05) 
MT-ND3 346 11 2.08E-05  (1.04E-05 - 3.73E-05) 
MT-ND4 1378 20 9.51E-06 (5.81E-06 - 1.47E-05) 
MT-ND4L 297 5 1.10E-05 (3.58E-06 - 2.57E-05) 
MT-ND5 1812 31 1.12E-05 (7.62E-06 - 1.59E-05) 
MT-ND6 525 12 1.50E-05 (7.74E-06 - 2.62E-05) 
MT-RNR1 954 20 1.37E-05 (8.39E-06 - 2.12E-05) 
MT-RNR2 1559 28 1.18E-05 (7.82E-06 - 1.70E-05) 
MT-tRNA 1508 39 1.69E-05 (1.21E-05 - 2.32E-05) 





Table S3. Two-sample Kolmogorov-Smirnov test of heteroplasmic variants between 
different mtDNA regions  
 
 mtDNA regions D P value 
Dloop vs non-syn 0.161 1.034E-06 
Dloop vs rRNA 0.246 3.011E-08 
Dloop vs tRNA  0.223 2.116E-05 
syn vs non-syn 0.149 2.740E-05 
syn vs rRNA 0.219 2.632E-06 
syn vs tRNA 0.197 3.845E-04 





Table S4. Numbers of observed heteroplasmic variants included in each nuclear and 
mtDNA ancestry group 
 







Matched Asian(646) 40 11 European(8533) 408 309 
MisMatched Asian(133) 14 5 European(73) 6 5 
Validation 
 dataset 
Matched Asian(2110) 140 70 European(21169) 1027 705 
MisMatched Asian(491) 39 12 European(185) 8 8 
 
Note: Numbers of the samples in each ancestry group are shown in the brackets, column Nuclear ancestry; Numbers 5 
of the unique haplogroup specific variants on the mtDNA phylogenetic tree are shown in the brackets at the top.





Table S5. Disease groups and the sample size of each group included in this study 
 
Disease 
Groups Unaffected Affected Unknown 
Total 
number Note 
BPD 41 1,123 0 1,164 ● Bleeding and platelet disorders 
CNTRL 50 0 0 50 ● Process control samples (unaffected anonymous donors) 
CSVD 10 145 91 246 ● Cerebral small vessel disease (stroke) 
EDS 0 17 0 17 ● Ehler-Danlos (ED) and ED-like syndromes 
GEL 2,199 2,619 0 4,818 ● 100 000 Genomes Project - Rare Diseases Pilot 
HCM 0 249 0 249 ● Hypertrophic cardiomyopathy 
ICP 0 268 0 268 ● Intrahepatic cholestasis of pregnancy 
IRD 0 715 0 715 ● Inherited retinal disorders 
LHON 24 47 0 71 ● Leber hereditary optic neuropathy (mitochrondrial disease) 
MPMT 37 532 0 582 ● Multiple primary malignant tumours 
NDD 186 473 13 659 ● Neurological and developmental disorders 
NPD 5 188 0 193 ● Neuropathic pain disorders 
PAH 22 1,082 38 1,142 ● Pulmonary arterial hypertension 
PID 350 984 14 1,348 ● Primary immune disorders 
PMG 0 184 0 184 ● Primary membranoproliferative glomerulonephritis 
SMD 117 125 13 255 ● Stem cell and myeloid disorders  ● (Red and white blood cell disorders) 
SRNS 15 236 0 251 ● Steroid resistant nephrotic syndrome 
UKBio 0 763 0 763 
● Extreme red blood cell traits, RBC 
(Red Blood Cell count) and MCV 
(Mean cell volume) from UK 
Biobank 
Total number 3,056 9,750 169 12,975  





Data S1. (separate file) 
List of heteroplasmic variants detected in 1,526 mother-offspring pairs 
